Arcturus Therapeutics (ARCT) Misses Q1 EPS by 90c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($2.15), $0.90 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $2.13 million versus the consensus estimate of $2.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Crocs upgraded to Overweight at Piper Sandler on North America recovery signs
• AB Science reports phase 1 data for AB8939 plus venetoclax in AML